Edesa Biotech Inc
EDSA
查看详细走势图
1.480USD
+0.006+0.39%
收盘 12/19, 16:00（美东）报价延迟15分钟
10.39M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.39%
5天
-14.94%
1月
-14.45%
6月
-24.49%
今年开始到现在
-11.90%
1年
-14.45%
查看详细走势图
TradingKey Edesa Biotech Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Edesa Biotech Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名168/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价11.00。中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Edesa Biotech Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
11.000
目标均价
+532.18%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Edesa Biotech Inc亮点
亮点风险
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
估值合理
公司最新PE估值-1.17，处于3年历史合理位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值45.54K
Edesa Biotech Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Edesa Biotech Inc简介
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
公司代码EDSA
公司Edesa Biotech Inc
CEONijhawan (Pardeep)
网址https://www.edesabiotech.com/
常见问题
Edesa Biotech Inc(EDSA)的当前股价是多少？
Edesa Biotech Inc(EDSA)的当前股价是 1.480。
Edesa Biotech Inc的股票代码是什么？
Edesa Biotech Inc的股票代码是EDSA。
Edesa Biotech Inc股票的52周最高点是多少？
Edesa Biotech Inc股票的52周最高点是4.490。
Edesa Biotech Inc股票的52周最低点是多少？
Edesa Biotech Inc股票的52周最低点是1.440。
Edesa Biotech Inc的市值是多少？
Edesa Biotech Inc的市值是10.39M。
Edesa Biotech Inc的净利润是多少？
Edesa Biotech Inc的净利润为-6.17M。
现在Edesa Biotech Inc(EDSA)的股票是买入、持有还是卖出？
根据分析师评级，Edesa Biotech Inc(EDSA)的总体评级为买入，目标价格为11.000。
Edesa Biotech Inc(EDSA)股票的每股收益（EPS TTM）是多少
Edesa Biotech Inc(EDSA)股票的每股收益（EPS TTM）是-1.270。
相关品种
